Imperial College London

ProfessorMichaelSchneider

Faculty of MedicineNational Heart & Lung Institute

Chair in Cardiology
 
 
 
//

Contact

 

+44 (0)013 34621727m.d.schneider Website

 
 
//

Location

 

ICTEM buildingHammersmith Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Golforoush:2020:10.1038/s41536-020-0090-7,
author = {Golforoush, P and Schneider, M},
doi = {10.1038/s41536-020-0090-7},
journal = {npj Regenerative Medicine},
pages = {1--9},
title = {Intensive care for human hearts in pluripotent stem cell models},
url = {http://dx.doi.org/10.1038/s41536-020-0090-7},
volume = {5},
year = {2020}
}

RIS format (EndNote, RefMan)

TY  - JOUR
AB - Successful drug discovery is ultimately contingent on the availability of workable, relevant, predictive model systems. Conversely, for cardiac muscle, the lack of human preclinical models to inform target validation and compound development has likely contributed to the perennial problem of clinical trial failures, despite encouraging non-human results. By contrast, human cardiomyocytes produced from pluripotent stem cell models have recently been applied to safety pharmacology, phenotypic screening, target validation and high-throughput assays, facilitating cardiac drug discovery. Here, we review the impact of human pluripotent stem cell models in cardiac drug discovery, discussing the range of applications, readouts, and disease models employed, along with the challenges and prospects to advance this fruitful mode of research further.
AU - Golforoush,P
AU - Schneider,M
DO - 10.1038/s41536-020-0090-7
EP - 9
PY - 2020///
SN - 2057-3995
SP - 1
TI - Intensive care for human hearts in pluripotent stem cell models
T2 - npj Regenerative Medicine
UR - http://dx.doi.org/10.1038/s41536-020-0090-7
UR - https://www.nature.com/articles/s41536-020-0090-7
UR - http://hdl.handle.net/10044/1/77683
VL - 5
ER -